Opportunity Information: Apply for PAR 12 222
Apply for PAR 12 222
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Cohort Studies of HIV/AIDS and Substance Use (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 17, 2014 and posted on Jun 29, 2012.
- Applicants must submit their applications by Dec 11, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal governments (Federally recognized) City or township governments Public housing authorities/Indian housing authorities State governments For profit organizations other than small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Cohort Studies of HIV/AIDS and Substance Use (U01) opportunity (Funding Opportunity Number PAR 12-222) is a National Institutes of Health program led by the National Institute on Drug Abuse (NIDA) that funds longitudinal cohort research focused on the intersection of HIV/AIDS and substance use. The core idea is to build, strengthen, or expand cohort infrastructures that can follow people over time in order to answer urgent and emerging questions about how substance use shapes HIV risk, prevention, disease progression, and treatment outcomes. Rather than supporting only a single short-term study, this announcement is designed to create durable research platforms that can generate ongoing scientific value, including data and specimens that can be leveraged for future investigator-initiated projects and broader collaborations.
The FOA specifically emphasizes longitudinal cohort studies, meaning applicants are expected to track individuals or groups across multiple time points to capture changes in behavior, exposure, health status, and clinical outcomes. NIDA is looking for cohorts that help clarify both the natural history of HIV infection (how infection and related health outcomes unfold over time in the real world) and the treated history (how treatment, engagement in care, adherence, and response to therapy progress), particularly in populations where substance use is a central driver of risk or a major complicating factor. In practice, that can include cohorts composed of people who use drugs, people with substance use disorders, or communities where substance use patterns significantly affect HIV transmission dynamics and care outcomes. The announcement’s framing also signals interest in research that can keep pace with changing epidemics, such as shifts in drug use patterns, evolving prevention strategies, and new treatment approaches.
This is a discretionary funding opportunity using a Cooperative Agreement mechanism (U01). A cooperative agreement generally means that NIH/NIDA expects substantial programmatic involvement during the project period compared with a typical research project grant, with the agency working alongside awardees on key aspects such as coordination, data harmonization, milestone-driven progress, or collaboration facilitation. The goal is to maximize the cohort’s usefulness as a shared scientific resource and to encourage efficient, coordinated research that can respond to new HIV and substance-use-related questions as they arise.
Eligible applicants are broad and include many types of U.S. and non-U.S. organizations. Domestic eligibility spans state, county, city/township, and special district governments; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; public and private institutions of higher education; independent school districts; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); and for-profit organizations (including small businesses and other for-profits). The FOA also explicitly includes a wide range of mission-specific and community-anchored institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Importantly, non-domestic (non-U.S.) entities (foreign institutions) may apply, and foreign components of U.S. organizations are permitted, consistent with NIH policy. There is no cost-sharing or matching requirement, which reduces barriers for applicants that might otherwise struggle to bring non-federal funds to the table.
From an administrative perspective, the opportunity is cataloged under CFDA 93.279 (Drug Abuse and Addiction Research Programs) and sits within the education/health activity category. The announcement was originally posted June 29, 2012, with later record creation noted September 17, 2014. The listed closing dates in the provided record include an original closing date of April 9, 2015 and a current closing date of December 11, 2014, and it was archived January 10, 2015, indicating it is no longer active. For historical reference and full details, the announcement was hosted at the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-12-222.html (spacing in the provided link reflects formatting, but the standard NIH URL uses PAR-12-222). The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
In plain terms, PAR 12-222 was aimed at creating or enhancing long-term cohort “backbones” that make it easier for the HIV and substance use research fields to answer complex, real-world questions that cannot be captured well in short snapshots. By investing in cohorts as shared platforms, NIDA intended to support both immediate high-priority studies and future collaborations that could rapidly pivot to emerging needs in HIV prevention and treatment where substance use is a key factor.
Frequently Asked Questions (FAQs)
What is the Cohort Studies of HIV/AIDS and Substance Use (U01) opportunity?
It is a National Institutes of Health (NIH) funding opportunity led by the National Institute on Drug Abuse (NIDA) to support longitudinal cohort research focused on the intersection of HIV/AIDS and substance use. The goal is to build, strengthen, or expand cohort infrastructures that can follow people over time and answer urgent and emerging questions about how substance use shapes HIV risk, prevention, disease progression, and treatment outcomes.
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR 12-222.
Which NIH institute leads this program?
The program is led by the National Institute on Drug Abuse (NIDA), part of NIH.
What type of funding mechanism is used?
This opportunity uses a Cooperative Agreement mechanism (U01). This generally means NIH/NIDA expects substantial programmatic involvement during the project period compared with a typical research project grant.
What does a Cooperative Agreement (U01) imply for awardees?
A U01 cooperative agreement indicates that NIH/NIDA may work alongside awardees on key aspects such as coordination, data harmonization, milestone-driven progress, or facilitating collaborations. The intent is to maximize the cohort's usefulness as a shared scientific resource and enable coordinated research that can respond to new HIV and substance-use-related questions as they arise.
What kinds of research does the FOA prioritize?
The FOA emphasizes longitudinal cohort studies that track individuals or groups across multiple time points. Applicants are expected to capture changes over time in behavior, exposure, health status, and clinical outcomes, especially where substance use is a central driver of HIV risk or a major complicating factor for prevention and treatment outcomes.
What does "longitudinal cohort study" mean in this context?
It means following the same individuals or defined groups over multiple time points, rather than collecting a single snapshot. This approach supports understanding how behaviors, exposures, and health outcomes evolve over time.
Is the FOA meant to fund a single short-term study?
No. The announcement is framed to support durable cohort "platforms" or infrastructures rather than only a single short-term study. The intent is to create research backbones that generate ongoing scientific value.
What is meant by building, strengthening, or expanding cohort infrastructures?
It refers to investing in the systems and structures needed to maintain cohorts over time, enabling repeated follow-up and producing data (and potentially specimens) that can support both immediate studies and future research projects and collaborations.
What scientific areas or questions is NIDA trying to address through these cohorts?
The cohorts are intended to answer urgent and emerging questions about how substance use influences HIV risk and transmission, HIV prevention, disease progression, and treatment outcomes. The FOA also signals interest in research that can adapt to changing epidemics, including shifts in drug use patterns, evolving prevention strategies, and new treatment approaches.
What does the FOA mean by the "natural history" of HIV infection?
It refers to how HIV infection and related health outcomes unfold over time in real-world settings, particularly in populations where substance use meaningfully affects risk or outcomes.
What does the FOA mean by the "treated history" of HIV?
It refers to how treatment and care unfold over time, including engagement in care, adherence, and response to therapy, especially in contexts where substance use may complicate care and outcomes.
Who are the populations of interest for these cohort studies?
Examples described include people who use drugs, people with substance use disorders, and communities where substance use patterns significantly affect HIV transmission dynamics and care outcomes. The FOA is focused on settings where substance use is a central driver of HIV risk or a major complicating factor.
Does the FOA encourage creating shared resources for the broader research community?
Yes. The announcement is designed to create durable research platforms that can generate ongoing value, including data and specimens that can be leveraged for future investigator-initiated projects and broader collaborations.
What kinds of collaboration or coordination might be expected?
Based on the description, NIH/NIDA involvement may include coordination across awardees, data harmonization efforts, milestone-driven progress expectations, and facilitation of collaborations to maximize the cohort's usefulness as a shared resource.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Domestic eligible entities include various levels of government (state, county, city/township, special district), federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, public and private institutions of higher education, independent school districts, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), and for-profit organizations (including small businesses and other for-profits).
Are mission-specific or community-anchored institutions included as eligible applicants?
Yes. The FOA explicitly includes entities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies.
Can non-U.S. (foreign) organizations apply?
Yes. Non-domestic (non-U.S.) entities (foreign institutions) may apply, and foreign components of U.S. organizations are permitted, consistent with NIH policy.
Is cost-sharing or matching required?
No. The FOA states there is no cost-sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The opportunity is cataloged under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
What is the activity category for this listing?
It is listed within the education/health activity category.
When was this FOA originally posted?
The announcement was originally posted on June 29, 2012.
Are there other dates noted in the record?
Yes. The record notes later record creation on September 17, 2014. It also lists closing dates that include an original closing date of April 9, 2015 and a current closing date of December 11, 2014, based on the provided record.
Is this funding opportunity currently active?
No. The record indicates it was archived on January 10, 2015, which means it is no longer active.
Where can the full FOA text be found for historical reference?
The announcement was hosted on the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-12-222.html
Who is listed as the contact for access or linking issues?
The contact listed is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the plain-language goal of PAR 12-222?
In plain terms, it aimed to create or enhance long-term cohort backbones so the HIV and substance use research fields could answer complex, real-world questions that short-term studies cannot capture well, and to support future collaborations that can pivot to emerging needs in HIV prevention and treatment where substance use is a key factor.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: High Energy Cost Grants
Previous opportunity: PPHF 2012 Cooperative Agreements for Prescription Drug Monitoring Program (PDMP) Electronic Health Record (EHR) Integration and Interoperability Expansion (PPHF 2012)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 12 222
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 12 222) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R21) Apply for PAR 12 229 Funding Number: PAR 12 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research on Interventions for Adolescents in the Legal System TRIALS (U01) Apply for RFA DA 13 009 Funding Number: RFA DA 13 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PAR 12 238 Funding Number: PAR 12 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Clinical Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PAR 12 239 Funding Number: PAR 12 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI National Clinical Trials Network Network Radiotherapy and Imaging Core Services Centers (U24) Apply for RFA CA 12 014 Funding Number: RFA CA 12 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Canadian Collaborating Clinical Trials Network (Limited Competition U10) Apply for RFA CA 12 504 Funding Number: RFA CA 12 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Operations Centers (U10) Apply for RFA CA 12 010 Funding Number: RFA CA 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10) Apply for RFA CA 12 011 Funding Number: RFA CA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10) Apply for RFA CA 12 012 Funding Number: RFA CA 12 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10) Apply for RFA CA 12 013 Funding Number: RFA CA 12 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 12 251 Funding Number: PAR 12 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 12 023 Funding Number: RFA CA 12 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R01) Apply for RFA DA 13 010 Funding Number: RFA DA 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R21) Apply for RFA DA 13 011 Funding Number: RFA DA 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R21 Apply for PA 12 274 Funding Number: PA 12 274 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 12 222", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.